Bone Density and Serum Testosterone in Male Methadone Maintained Patients

Osteoporosis Clinical Trial

Official title:

Bone Density and Serum Testosterone in Male Methadone Maintained Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00170339
• Other study ID #: HSR-04-2404
• Secondary ID: 0409M63575
• Status: Completed
• Phase: N/A
• First received: September 9, 2005
• Last updated: September 12, 2016
• Start date: April 2005
• Est. completion date: April 2007

Study information

• Verified date: September 2016
• Source: Minneapolis Medical Research Foundation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

This is a pilot study designed to answer the question " Do men who are receiving methadone maintenance therapy have lower spinal bone densities compared with age-matched controls who are not receiving methadone therapy?"

The primary aim is to assess whether the mean or median spinal dual-ray energy x-ray absorptiometry (DEXA) scan results are different between these two groups of male patients. Primary measurements include: spinal bone densitometry by DEXA scan.

The secondary aim is to examine the role of sex steroids in men receiving methadone maintenance therapy and their association with spinal bone density and sexual dysfunction. Secondary measurements include: serum testosterone, estradiol, lutenizing hormone, albumin, sex hormone binding globulin and Vitamin D levels; age; Brief Sexual Function Inventory; Dietary, smoking/alcohol use and physical activity; Medical history, surgical and medication use; length of time using illicit opiates and time on methadone maintenance therapy.

Description:

Chronic use of opiates has long been associated with multiple side effects, many of which are due to lower levels of androgens in this patient population. Previous studies have shown that long-term opiate use may lead to narcotic induced hypogonadism, resulting in significantly decreased testosterone levels in men. One area of chronic opiate use that has not been looked at extensively is the correlation between narcotic-induced hypogonadism and associated side effects such as osteoporosis and sexual dysfunction in male patients receiving methadone maintenance therapy. Marked testosterone deficiency is a well-established rick factor for both osteoporosis and altered sexual function, and recent information demonstrated that altered estrogen levels may play a role in these side effects as well. Thre present pilot study investigates the role of sex steroids in male patients maintained on methadone therapy and their association with bone densitometry and sexual dysfunction. Free testosterone, estradiol, lutenizing hormone, sex hormone binding globulin, Vitamin D levels and albumin will be measured in thirty community-dwelling outpatient men participating in a methadone maintenance program as well as thirty age-matched controls from a general medicine clinic. Osteodensitometry will be performed with the DEXA technique at the lumbar spine. Participants will also complete the Brief Male Sexual Function Inventory as well as be assessed for smoking/alcohol use, calcium intake, physical activity, length of time receiving opiates as well as concurrent medications. It is hypothesized that patients receiving methadone maintenance therapy will have lower bone mass densities, free testosterone, estradiol, and sexual dysfunction scores than the age-matched controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• age 18 to 50

• methadone maintenance for at least 12 months (for cases)

• stable dose of methadone for 6 months (for cases)

• willing to participate in the study

• competency in English

• male

Exclusion Criteria:

• previous diagnosis of sexual dysfunction

• previous diagnosis of osteoporosis

• serum creatinine > 2 mg/dL

• chronic opiate use (for controls)

• congestive heart failure

• illicit drug use

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Erectile Dysfunction
• Hypogonadism
• Opiate Dependence
• Opioid-Related Disorders
• Osteoporosis

Locations

Country	Name	City	State
United States	Hennepin Faculty Associates/ Hennepin County Medical Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Minneapolis Medical Research Foundation

Country where clinical trial is conducted

United States,